Donafenib in Chinese patients with advanced hepatocellular carcinoma (HCC): Really a new standard of care, or should we change paradigm for drug development in HCC?

• Francesca Negri,
• Camillo Porta

Affiliations

Francesca Negri

Medical Oncology Unit, University Hospital of Parma, Parma

Camillo Porta

Department of Biomedical Sciences & Human Oncology, University of Bari ‘Aldo Moro’, and Division of Medical Oncology, Azienda Ospedaliero-Universitaria Consorziale Policlinico, Bari